Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Chiorean on Combination Therapies for Pancreatic Cancer

Gabriela Chiorean, MD
Published: Wednesday, Jan 25, 2017



Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

There is an ongoing clinical trial for patients with pancreatic cancer that uses nivolumab (Keytruda) and nab-paclitaxel (Abraxane)-based combinations, explains Chiorean. It started with nivolumab and nab-paclitaxel for patients in the second-line setting and was moved to the first-line setting with nivolumab, nab-paclitaxel, and gemcitabine (Gemzar). The main goals of the study are safety and preliminary efficacy.

It was shown that nivolumab did not seem to add any significant toxicity to the chemotherapy regimen. One of the patients experienced a grade 3 dose-limiting toxicity of liver enzyme elevations, which was attributed to chemotherapy. The adverse event quickly resolved after a chemotherapy dose-reduction and nivolumab was resumed at full dose, reinforcing that it was not an immune-related event.
 


Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

There is an ongoing clinical trial for patients with pancreatic cancer that uses nivolumab (Keytruda) and nab-paclitaxel (Abraxane)-based combinations, explains Chiorean. It started with nivolumab and nab-paclitaxel for patients in the second-line setting and was moved to the first-line setting with nivolumab, nab-paclitaxel, and gemcitabine (Gemzar). The main goals of the study are safety and preliminary efficacy.

It was shown that nivolumab did not seem to add any significant toxicity to the chemotherapy regimen. One of the patients experienced a grade 3 dose-limiting toxicity of liver enzyme elevations, which was attributed to chemotherapy. The adverse event quickly resolved after a chemotherapy dose-reduction and nivolumab was resumed at full dose, reinforcing that it was not an immune-related event.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x